Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Cutia Therapeutics's interest expense for the
six
months ended in Dec. 2025 was HK$ -5.3 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-10.7 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Cutia Therapeutics's Operating Income for the
six
months ended in Dec. 2025 was HK$ -105.1 Mil. Cutia Therapeutics's Interest Expense for the
six
months ended in Dec. 2025 was HK$ -5.3 Mil.
Cutia Therapeutics did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Cutia Therapeutics's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as
Cutia Therapeutics did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Cutia Therapeutics Interest Expense Historical Data
* Premium members only.
The historical data trend for Cutia Therapeutics's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-10.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Expense of HK$-10.7 Mil mean?
Cutia Therapeutics (HKSE:02487) has a Interest Expense of HK$-10.7 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Cutia Therapeutics and its competitors.
Is Cutia Therapeutics' Interest Expense too high?
Cutia Therapeutics' current Interest Expense is HK$-10.7 Mil. Overall, Cutia Therapeutics has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cutia Therapeutics' Interest Expense compare to VRTX and REGN?
Cutia Therapeutics' Interest Expense of HK$-10.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Cutia Therapeutics and its competitors. Cutia Therapeutics's current Interest Expense is HK$-10.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cutia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Cutia Therapeutics (HKSE:02487) is currently considered Possible Value Trap. The stock's GF Value™ is HK$16.42, compared to a current price of HK$2.50 — trading 84.8% below its estimated fair value. The current Interest Expense is HK$-10.7 Mil. Cutia Therapeutics' overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Cutia Therapeutics (HKSE:02487), the current Interest Expense is HK$-10.7 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cutia Therapeutics (HKSE:02487) Overvalued in 2026?
Based on GuruFocus' analysis, Cutia Therapeutics stock appears to be undervalued.
The current stock price of HK$2.50 is trading 84.8% below its estimated GF Value™ of HK$16.42.
GuruFocus considers Cutia Therapeutics to be Possible Value Trap.
Key valuation signals for HKSE:02487:
Interest Expense: HK$-10.7 Mil
GF Value™: HK$16.42 vs. price of HK$2.50 (84.8% below fair value)
No single metric tells the full story. See the HKSE:02487 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cutia Therapeutics is an investment holding company. The Company and its subsidiaries are principally engaged in developing inventive and comprehensive solutions that are tailored to meet the diverse and evolving needs of patients and consumers in the broader dermatology treatment and care market. It has a proprietary CATAME technology platform, which includes: Colloidal-Emulsification-Active Encapsulation (CEAE) platform, Aerosol (ARS) platform, Transdermal Delivery (TDD) platform, Actives & Formulation Evaluation (AFE) platform, Micro/Nano-Particulates & Self-Assembly (MiSA) platform, and Ex vivo & Efficacy Evaluation (EVEE) platform. It enables the development of a wide range of product dosage forms and the relevant formulation technology.
42GF Score
Get the complete analysis for HKSE:02487
Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02487 has been successfully added to your 
